Lupin gets USFDA approval for generic Safyral Tablets
Tanay Loya / 14 Dec 2017
Lupin on Thursday announced that it has received final approval from USFDA for Tydemy drug used for contraception.
Lupin on Thursday announced that it has received final approval from USFDA for Tydemy drug used for contraception.
The pharma bellwether has received final approval for its Tydemy-Ethinyl Estradiol, Drospirenone and Levomefolate Calcium tablets- from the US Food and Drug Administration (USFDA) to market a generic version of Safyral tablets of Bayer Healthcare Pharmaceuticals.
Tydemy can be used to prevent pregnancy and to increase folate levels in women who choose to use an oral contraceptive for contraception. The tablets had annual sales of approximately US$ 22.9 million in the US market.
Lupin Limited is a transnational pharmaceutical company based in Mumbai and is among the top five pharma companies in India.
On Thursday, Lupin closed at Rs. 852.80 per share, up Rs. 7.55, or 0.89 per cent on the NSE. The scrip opened at Rs 845.65 and touched a high and low of Rs. 843.60 and Rs. 855.95, respectively. The stock has a 52-week high and 52-week low of Rs. 806.26 and 1,573.60, respectively. The stock attracted a traded volume of 15,27,566 shares on NSE.
If you want to stay updated with the share market news today, keep a close watch on the indian stock market today with real time movements like sensex today live and overall stock market today trends. Investors tracking ipo allotment status, ipo news today, or the latest ipo india can also follow daily updates along with bse share price live data. Whether you are learning how to invest in stock market in india, preparing for a market crash today, or searching for the best stocks to buy in india, insights on top gainers today india, top losers today india, trending stocks india and long term stocks india help in making informed investment decisions.